Cantor Fitzgerald lowered the firm’s price target on MiMedx (MDXG) to $8 from $12 and keeps an Overweight rating on the shares. The firm is adjusting its model to reflect the announcement by CMS that the Medicare Administrative Contractors withdrew the finalized skin substitute local cost determinations that had been scheduled to take effect on January 1, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG: